What Will Trump's Presidency Mean for Pharma Stocks?
In the days following the American presidential election, pharmaceutical stocks soared. The market’s response was more in response to Clinton’s loss than Trump’s victory—while the Democratic nominee was a vocal critic of the pharmaceutical industry, Trump’s position always seemed less clear. Nevertheless, investors have welcomed the unknown: as CNBC reports, the drug industry has gained almost ten percent since election day.
The question, of course, is whether that rally can continue.
Trump’s stance
“Repeal and replace”: during the campaign, this was Trump’s unequivocal stance on Obamacare. But he wasn’t so vocal on other topics, like pharmaceutical pricing or so-called pay-for-delay deals—both of which his opponent denounced. That means there are plenty of question marks going into the next four years.
With January fast approaching, it’s worthwhile to reexamine Trump’s stance on various industry-related questions, like Medicare’s negotiating power or selling foreign-manufactured drugs domestically.
Medicare’s negotiating power
During the...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin